ArticleVaccine2022
Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review.BMC public health · 2023Pooled it
- HPV vaccination policies and implementation for adolescents in low- and middle-income countries: a scoping review.The Lancet regional health. Western Pacific · 2026Review
- Article
- Cervical Cancer Knowledge, Attitudes, and Practices Among Informal Sector Women: Prevention Challenges in Eastern Democratic Republic of the Congo.International journal of women's health · 2026Article
- Introduction of the HPV Vaccine among Young Girls to Reduce the Long-Term Risk of Cervical Cancer in Eswatini: Programmatic Decision and Roll Out.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Behavioural and Social Drivers (BeSD) of HPV vaccination in Zimbabwe: A Rapid Scoping Review of Literature.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Trends in gastrointestinal cancer burden in Zimbabwe: 10-year retrospective study 2009-2018.Ecancermedicalscience · 2025Article
- Cervical cancer awareness among women recently diagnosed with cervical cancer in South Africa and Zimbabwe.Ecancermedicalscience · 2025Article
- Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: an updated review.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Exploring the complexity of the implementation determinants of human papillomavirus vaccination in Africa through a systems thinking lens: A rapid review.Human vaccines & immunotherapeutics · 2024Review
- Vaccination Effectiveness against Human Papillomavirus in Kazakhstan.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Improving HPV Vaccination Uptake Among Adolescents in Low Resource Settings: Sociocultural and Socioeconomic Barriers and Facilitators.Adolescent health, medicine and therapeutics · 2024Review
- Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.Frontiers in immunology · 2023Review
- Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: What works in the context of low-resource countries?Frontiers in public health · 2023Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionZimbabwe introduced human papillomavirus (HPV) vaccine nationally in May 2018, targeting multiple cohorts (girls aged 10-14 years) through a school-based vaccination campaign. One year later, the second dose was administered to the multiple cohorts concurrently with the first dose given to a new single cohort of girls in grade 5. We conducted cross-sectional surveys among health workers, school personnel, and community members to assess feasibility of implementation, training, social mobilization, and community acceptability.
methodsThirty districts were selected proportional to the volume of the HPV vaccine doses delivered in 2018; two health facilities were randomly selected within each district. One health worker, school health coordinator, village health worker, and community leader were surveyed at each selected health facility and surrounding area during January-February 2020, using standard questionnaires. Descriptive analysis was completed across groups.
resultsThere were 221 interviews completed. Over 60% of health workers reported having enough staff to carry out vaccination sessions in schools while maintaining routine vaccination services in health facilities. All school health coordinators felt the HPV vaccine should be delivered in schools in the future. Knowledge of the correct target cohort eligibility decreased from 91% in 2018 to 50% in 2020 among health workers. Understanding of HPV infection and use of HPV vaccine for cervical cancer prevention was above 90% for all respondents. Forty-two percent of respondents reported hearing rumors about the HPV vaccine, primarily regarding infertility and safety.
conclusionsFindings demonstrate the presence of highly knowledgeable staff at health facilities and schools, strong community acceptance, and a school-based HPV program considered feasible to implement in Zimbabwe. However, misunderstandings regarding target eligibility and rumors persist, which can impact vaccine uptake and coverage. Continued social mobilization efforts to maintain community demand and training on eligibility were recommended. Integration, partnerships, and resource mobilization are also needed to ensure program sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.